Alison Tree answers five questions about their experience with Elekta Unity

Dr. Alison Tree, MD from the Institute of Cancer Research and The Royal Marsden Hospital (RMH), UK, shares her initial experience with the Elekta Unity MR-Linac, highlights the PRISM clinical trial, and reflects on the impact of this technology on both treatment outcomes and patient experience.

What has your initial experience with Elekta Unity been like?

• Treated 10 patients with prostate cancer and 2 with rectal cancer
• Observed no unexpected toxicities and achieved positive treatment outcomes

What is the PRISM Study?

•  A clinical trial for men with prostate cancer
• Delivers 60 Gy in 20 fractions over 4 weeks
• Treatment plans are adapted daily based on anatomical changes, thanks to Elekta Unity's advanced imaging and adaptive capabilities

How are you using Elekta Unity in your practice?

• Looking ahead to hypofractionated treatment—delivering fewer, higher-dose sessions
• Unity’s adaptive precision supports this shift, potentially reducing treatment times

What stands out most about Elekta Unity?

• Provides unprecedented visibility into anatomical changes
• Showcases the variation between patients, allowing truly personalized care
• The ability to adapt treatment plans in real time is a game changer

What has the patient response been?

• Overwhelmingly positive feedback
• Low levels of anxiety
• Patients appreciate the high level of precision and care